Efficacy and safety studies of a recombinant chimeric respiratory syncytial virus FG glycoprotein vaccine in cotton rats

Journal of Virology

Volumn 74, Issue 22, 2000, Pages 10287-10292

  Prince, G A ^a   Capiau, C ^a   Deschamps, M ^a   Fabry, L ^a   Garcon, N ^a   Gheysen, D ^a   Prieels, J P ^a   Thiry, G ^a   Van Opstal, O ^a   Porter, D D ^a  

^a Virion Systems Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE; VIRUS GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHIMERA; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; IMMUNE RESPONSE; IMMUNOGENICITY; INTERSTITIAL PNEUMONIA; LUNG ALVEOLITIS; LUNG INFECTION; NONHUMAN; PRIORITY JOURNAL; RAT; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VACCINATION; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS TITRATION;

ANIMALS; ANTIBODIES, VIRAL; LUNG; LUNG DISEASES, INTERSTITIAL; NEUTRALIZATION TESTS; PNEUMONIA, VIRAL; RECOMBINANT FUSION PROTEINS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; SIGMODONTINAE; VACCINATION; VIRAL PROTEINS;

EID: 0033761655     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.22.10287-10292.2000     Document Type: Article

References (36)

1. Complete protection of mice from respiratory syncytial virus infection following mucosal delivery of synthetic peptide vaccine
2. Molecular cloning and sequencing of the F and 22K membrane protein genes of the RSS-2 strain of respiratory syncytial virus
3. Parenteral administration of live respiratory syncytial virus vaccine: Results of a field trial
4. Protection of cotton rats against human respiratory syncytial virus by vaccination with a novel chimeric FG glycoprotein
5. Partial protection to respiratory syncytial virus (RSV) elicited in mice by intranasal immunization using live staphylococci with surface-displayed RSV-peptides
6. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population
7. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia-RSV recombinants or RSV
8. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10
9. + T cells
10. Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV). A meeting report of the WHO programme for vaccine development
11. A prototype recombinant vaccine against respiratory syncytial virus and parainfluenza virus type 3
12. Respiratory syncytial virus vaccines
13. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines: An aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine
14. Influence of administration dose and route on the immunogenicity and protective efficacy of BBG2Na, a recombinant respiratory syncytial virus subunit vaccine candidate
15. The immunogenicity of subunit vaccines for respiratory syncytial virus after co-formulation with aluminum hydroxide adjuvant and recombinant interleukin-12
16. Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children
17. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine
18. Safety and antigenicity of temperature sensitive (is) mutant respiratory syncytial virus (RSV) in infants and children
19. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine
20. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate
21. Detection of respiratory syncytial virus (RSV) infected cells by in situ hybridization in the lungs of cotton rats immunized with formalin-inactivated virus or purified RSV F and G glycoprotein subunit vaccine and challenged with RSV
22. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization
23. Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine
24. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis
25. Absence of lung immunopathology following respiratory syncytial virus (RSV) challenge in mice immunized with a recombinant RSV G protein fragment
26. Parenteral immunization with live respiratory syncytial virus is blocked in seropositive cotton rats
27. Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats
28. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by intramuscular inoculation of formalin-inactivated virus
29. The pathogenesis of respiratory syncytial virus infection in cotton rats
30. Pulmonary lesions in primary respiratory syncytial virus infection, reinfection, and vaccine-enhanced disease in the cotton rat (Sigmodon hispidus)
31. Effective mucosal immunization against respiratory syncytial virus using purified F protein and a genetically detoxified cholera holotoxin, CT-E29H
32. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system
33. Characterization of a novel human respiratory syncytial virus chimeric FG glycoprotein expressed using a baculovirus vector
34. Nucleotide sequence of the G protein gene of human respiratory syncytial virus reveals an unusual type of viral membrane protein
35. Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children
36. Evaluation of a live, attenuated respiratory syncytial virus vaccine in infants